UB Paderborn / Katalog / Suche / in CDI

The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score

British journal of dermatology (1951), 2012-05, Vol.166 (5), p.971-975

2012

Link zum Volltext

Verfügbarkeit prüfen

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

Annals of the Rheumatic Diseases, 2010-07, Vol.69 (7), p.1269-1274

2010

Link zum Volltext

Verfügbarkeit prüfen

The impact of skin damage due to cutaneous lupus on quality of life

British journal of dermatology (1951), 2014-02, Vol.170 (2), p.315-321

2014

Link zum Volltext

Verfügbarkeit prüfen

Biological therapies in the treatment of cutaneous lupus erythematosus

Lupus, 2017-02, Vol.26 (2), p.115-118

2017

Link zum Volltext

Verfügbarkeit prüfen

TNF-α production in the skin

Archives of Dermatological Research, 2009, Vol.301 (1), p.87-91

2009

Link zum Volltext

Verfügbarkeit prüfen

Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.853-854

2017

Link zum Volltext

Verfügbarkeit prüfen

Importance of recognition and improved treatment for antimelanoma differentiation‐associated protein 5‐associated dermatomyositis

British journal of dermatology (1951), 2017-11, Vol.177 (5), p.1168-1169

2017

Link zum Volltext

Verfügbarkeit prüfen

无肌病性皮肌炎的诊断和分类

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.e174-e174

2019

Link zum Volltext

Verfügbarkeit prüfen

白细胞介素‐31和皮肌炎瘙痒

British journal of dermatology (1951), 2018-09, Vol.179 (3), p.e164-e164

2018

Link zum Volltext

Verfügbarkeit prüfen

A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus

British journal of dermatology (1951), 2013-01, Vol.168 (1), p.145-153

2013

Link zum Volltext

Verfügbarkeit prüfen

Cutaneous lupus erythematosus: Diagnosis and treatment

Best practice & research. Clinical rheumatology, 2013-06, Vol.27 (3), p.391-404

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

British journal of dermatology (1951), 2017-01, Vol.176 (1), p.231-233

2017

Link zum Volltext

Verfügbarkeit prüfen

Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument

British journal of dermatology (1951), 2010-03, Vol.162 (3), p.669-673

2010

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists

British journal of dermatology (1951), 2017-10, Vol.177 (4), p.1086-1092

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

British journal of dermatology (1951), 2008-10, Vol.159 (4), p.887-894

2008

Link zum Volltext

Verfügbarkeit prüfen

The role of cytokines in the pathogenesis of cutaneous lupus erythematosus

Cytokine (Philadelphia, Pa.), 2015-06, Vol.73 (2), p.326-334

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome measures for cutaneous lupus erythematosus

Lupus, 2010-08, Vol.19 (9), p.1137-1143

2010

Link zum Volltext

Verfügbarkeit prüfen

The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists

British journal of dermatology (1951), 2017-02, Vol.176 (2), p.423-430

2017

Link zum Volltext

Verfügbarkeit prüfen

Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis

British journal of dermatology (1951), 2017-01, Vol.176 (1), p.262-264

2017

Link zum Volltext

Verfügbarkeit prüfen

Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.949-954

2020

Link zum Volltext

Verfügbarkeit prüfen

A double‐blind, randomized, placebo‐controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.964-965

2019

Link zum Volltext

Verfügbarkeit prüfen

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study

British journal of dermatology (1951), 2021-10, Vol.185 (4), p.745-755

2021

Link zum Volltext

Verfügbarkeit prüfen

儿科皮肤病专家和风湿病专家对 CLASI 的评估

British journal of dermatology (1951), 2019-01, Vol.180 (1), p.e24-e24

2019

Link zum Volltext

Verfügbarkeit prüfen

Cross‐cultural adaptations of health‐related quality of life measures

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.659-660

2019

Link zum Volltext

Verfügbarkeit prüfen

The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review

Seminars in arthritis and rheumatism, 2020-06, Vol.50 (3), p.458-462

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

The impact of skin damage due to cutaneous lupus on quality of life

Biological therapies in the treatment of cutaneous lupus erythematosus

TNF-α production in the skin

Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis

Importance of recognition and improved treatment for antimelanoma differentiation‐associated protein 5‐associated dermatomyositis

无肌病性皮肌炎的诊断和分类

白细胞介素‐31和皮肌炎瘙痒

A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus

Cutaneous lupus erythematosus: Diagnosis and treatment

Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument

Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

The role of cytokines in the pathogenesis of cutaneous lupus erythematosus

Clinical outcome measures for cutaneous lupus erythematosus

The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists

Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis

Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis

A double‐blind, randomized, placebo‐controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study

儿科皮肤病专家和风湿病专家对 CLASI 的评估

Cross‐cultural adaptations of health‐related quality of life measures

The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review

Suchergebnisse filtern